• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Bemnifosbuvir and remdesivir inhibit tick-borne encephalitis virus infection in complementary in vitro and ex vivo disease models.

Bemnifosbuvir and remdesivir inhibit tick-borne encephalitis virus infection in complementary in vitro and ex vivo disease models.

Details
Files
DOI
10.48620/98403
Publisher DOI
10.1016/j.antiviral.2026.106439
PubMed ID
42177917
Abstract
The geographical distribution and incidence of tick-borne encephalitis (TBE) have steeply increased over the past decades, raising to represent a major health concern in Asia and Europe. Symptoms of TBE, caused by infections with tick-borne encephalitis virus (TBEV), range from mild, flu-like symptoms to severe neurological disease, often accompanied by long-term sequelae persisting for several years following pathogen encounter. While effective vaccines against TBEV are available, no antiviral drugs are currently approved and therapeutic options for patients suffering from TBE are limited to supportive measures. Compounds able to disrupt viral nucleic acid synthesis bear the potential of effectively limiting viral replication and spread. Seeking to fill the therapeutic gap, we evaluated the efficacy of a panel of approved and investigational antiviral compounds in containing TBEV infection. Combining several cell lines, human neural organoids and organotypic rat brain slice cultures, we found that the nucleoside analogs remdesivir and bemnifosbuvir efficiently limit viral replication. Through infectious virus quantification, immunofluorescence analysis and flow cytometry, we report significant, dose-dependent reduction of viral loads across all models used, with inhibition observed at low doses for both drugs. Notably, while we observed bemnifosbuvir to be well tolerated, we report important cytotoxicity of remdesivir when applied to human neural organoids. Our findings identify bemnifosbuvir and remdesivir as novel treatment strategies for TBE, providing an accessible and timely response to a clinical challenge of pressing concern.
Date Issued
2026-07
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
500 Science > 590 Animals (Zoology)
500 Science > 570 Life sciences; biology
Subjects
ProTide technology
•
antiviral therapy
•
brain organoids
•
brain organotypic cultures
•
flavivirus
•
nucleotide analogs
•
tick-borne encephalitis virus
Language(s)
en
Author(s)
Leoni, Simone  
Institute for Infectious Diseases, Research  
Institut für Infektionskrankheiten (IFIK) - Neuroinfection  
Graduate School for Cellular and Biomedical Sciences (GCB)  
Schultz-Pernice, Isabel  
Institute of Virology and Immunology  
Graduate School for Cellular and Biomedical Sciences (GCB)  
Department of Infectious Diseases and Pathobiology (DIP)  
Krátka, Zuzana
Freiholz, Lucie  
Institut für Infektionskrankheiten (IFIK) - Microbiome  
Institute for Infectious Diseases  
Fahmi, Amal  
Institute of Virology and Immunology  
Department of Infectious Diseases and Pathobiology (DIP)  
David, Teodora  
Institute of Virology and Immunology  
Department of Infectious Diseases and Pathobiology (DIP)  
Golomingi, Antoinette  
Institute of Virology and Immunology  
Department of Infectious Diseases and Pathobiology (DIP)  
Blank, Fabian  
Department for BioMedical Research, Live Cell Imaging (LCI)  
Department for BioMedical Research (DBMR)  
Department for BioMedical Research, Forschungsgruppe Pneumologie (Erwachsene)  
Clinic of Pneumology and Allergology  
Beránková, Michaela
Dejmek, Milan
Grandgirard, Denis  
Institut für Infektionskrankheiten (IFIK) - Neuroinfection  
Institute for Infectious Diseases, Research  
Dijkman, Ronald  
Institute for Infectious Diseases, Research  
Institute for Infectious Diseases - Experimental Virology  
Růžek, Daniel
Eyer, Luděk
Alves, Marco P.  
Institute of Virology and Immunology  
Department of Infectious Diseases and Pathobiology (DIP)  
Leib, Stephen L.  
Institute for Infectious Diseases, Research  
Institut für Infektionskrankheiten (IFIK) - Neuroinfection  
Institute for Infectious Diseases  
Department of Infectious Diseases and Pathobiology (DIP)  
Additional Credits
Department of Infectious Diseases and Pathobiology (DIP)  
Institut für Infektionskrankheiten (IFIK) - Neuroinfection  
Graduate School for Cellular and Biomedical Sciences (GCB)  
Department for BioMedical Research (DBMR)  
Institute for Infectious Diseases  
Institute for Infectious Diseases - Experimental Virology  
Institute of Virology and Immunology  
Institute for Infectious Diseases, Research  
Department for BioMedical Research, Live Cell Imaging (LCI)  
Institut für Infektionskrankheiten (IFIK) - Microbiome  
Department for BioMedical Research, Forschungsgruppe Pneumologie (Erwachsene)  
Clinic of Pneumology and Allergology  
Journal
Antiviral Research
Publisher
Elsevier
ISSN
1872-9096
0166-3542
0166-3542
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify